SCOLI PRO Epigenetics

SCOLI PRO Genetics is an epigenetic test developed in conjunction with EpiDisease, an investee company of ARQUIMEA, enabling to improve the monitoring and planning of treatments for Adolescent Idiopathic Scoliosis (AIS).

The AIS is a multifactorial disease in which both the individual’s genetics and the environmental factors, known as epigenetics, contribute to its onset and progression. Therefore, the early diagnosis is basic to avoid worsening of this pathology in adolescents.

The SCOLI PRO test identifies genetic and epigenetic biomarkers which allow to predict the response of the patient to a brace-based treatment, for example, enabling the doctor to plan the most effective treatments.